Journal of Cancer Research and Clinical Oncology

, Volume 132, Issue 11, pp 709–717

The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma

  • Hui Zhang
  • Qing-Hai Ye
  • Ning Ren
  • Lei Zhao
  • Yan-Fang Wang
  • Xin Wu
  • Hui-Chuan Sun
  • Lu Wang
  • Bo-Heng Zhang
  • Yin-Kun Liu
  • Zhao-You Tang
  • Lun-Xiu Qin
Original Paper

Abstract

We aimed to evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in 101 patients with hepatocellular carcinoma (HCC) who underwent liver resection. Plasma OPN levels were detected by ELISA. The association of plasma OPN levels of patients with clinicopathological characteristics, tumor recurrence, and survival was analyzed. The median plasma OPN level of patients was 176.90 ng/ml (range 13.73–780.00 ng/ml), which was significantly higher than that of 24 healthy volunteers (63.74 ng/ml, range 12.20–122.32 ng/ml). Plasma OPN levels were significantly different in patients with different numbers of tumor nodules (168.18 and 217.11 ng/ml for single and multiple nodules, respectively; P = 0.002), different Edmondson’s grades (201.24, 168.36, and 503.58 ng/ml for grades I, II, and III/IV, respectively; P = 0.015), and different TNM stages (168.16, 167.54, and 216.18 ng/ml for stages I, II, and III/IV, respectively; P = 0.016). Significantly higher plasma OPN levels were found in patients with a recurrence of HCC after resection, compared with those without recurrence (213.55 versus 153.70 ng/ml; P = 0.0013). A higher plasma OPN level was a leading independent prognostic factor for both overall survival (OS) and disease-free survival (DFS) in univariate and multivariate Cox models. This suggests that the preoperative plasma OPN level can be used as a predictive marker for HCC recurrence and may be helpful to assess the prognosis of patients with HCC after surgery.

Keywords

Hepatocellular carcinoma Recurrence Metastasis Prognosis Osteopontin 

Abbreviations

HCC

Hepatocellular carcinoma

OPN

Osteopontin

AFP

Alpha fetoprotein

IQR

Interquartile range

DFS

Disease-free survival

OS

Overall survival

References

  1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521PubMedGoogle Scholar
  2. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O’Malley FP, Singhal H, Tokmakejian S, Bramwell V, Harris JF (1996) Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 29:231–239PubMedCrossRefGoogle Scholar
  3. Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457PubMedCrossRefGoogle Scholar
  4. Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF (2005) Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 4:1336–1341PubMedCrossRefGoogle Scholar
  5. Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88:912–920PubMedCrossRefGoogle Scholar
  6. Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437–444PubMedCrossRefGoogle Scholar
  7. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758PubMedCrossRefGoogle Scholar
  8. Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15:311–323PubMedCrossRefGoogle Scholar
  9. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS (1997) Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14:1581–1588PubMedCrossRefGoogle Scholar
  10. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190PubMedCrossRefGoogle Scholar
  11. Crawford HC, Matrisian LM, Liaw L (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206–5215PubMedGoogle Scholar
  12. Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723–749PubMedCrossRefGoogle Scholar
  13. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J (1998) Trends in primary liver cancer. Lancet 351:215–216PubMedCrossRefGoogle Scholar
  14. Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465PubMedCrossRefGoogle Scholar
  15. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRefGoogle Scholar
  16. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535PubMedCrossRefGoogle Scholar
  17. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMedGoogle Scholar
  18. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118:2255–2261PubMedCrossRefGoogle Scholar
  19. Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632PubMedCrossRefGoogle Scholar
  20. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19–24PubMedCrossRefGoogle Scholar
  21. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134PubMedCrossRefGoogle Scholar
  22. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506–512PubMedCrossRefGoogle Scholar
  23. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao YZ (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652PubMedCrossRefGoogle Scholar
  24. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer Statistics 2003. CA Cancer J Clin 53:5–26PubMedGoogle Scholar
  25. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671–1679CrossRefGoogle Scholar
  26. Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Azuma M, Yara S, Shinzato T, Higa F, Tateyama M, Kadota JI, Mukae H, Kohno S, Uede T, Saito A (2003) High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 167:1355–1359PubMedCrossRefGoogle Scholar
  27. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67PubMedGoogle Scholar
  28. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K (2004) Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 29:202–206PubMedCrossRefGoogle Scholar
  29. Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, Comoglio PM (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61:5861–5868PubMedGoogle Scholar
  30. Oates AJ, Barraclough R, Rudland PS (1996) The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97–104PubMedGoogle Scholar
  31. O’Regan A, Fleming C (2002) Comment on: JAMA 2002, 287:1671–1679. Osteopontin as a biomarker for ovarian cancer. JAMA 287:3208–3210Google Scholar
  32. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127PubMedCrossRefGoogle Scholar
  33. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  34. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29PubMedCrossRefGoogle Scholar
  35. Qin LX, Tang ZY (2004) Recent progresses in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a literatures review. J Cancer Res Clin Oncol 130:497–513PubMedCrossRefGoogle Scholar
  36. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881PubMedCrossRefGoogle Scholar
  37. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMedGoogle Scholar
  38. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123:263–270PubMedCrossRefGoogle Scholar
  39. Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611PubMedGoogle Scholar
  40. Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135–146PubMedGoogle Scholar
  41. Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, LondonGoogle Scholar
  42. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11:279–303PubMedCrossRefGoogle Scholar
  43. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A (2002) Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441:345–349PubMedCrossRefGoogle Scholar
  44. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187–196PubMedCrossRefGoogle Scholar
  45. Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S, Shimada M, Maehara S, Maehara Y, Tsuneyoshi M (2004) Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int 24:38–45PubMedCrossRefGoogle Scholar
  46. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271–2277PubMedGoogle Scholar
  47. Tuck AB, O’Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502–508PubMedCrossRefGoogle Scholar
  48. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79:127–132PubMedCrossRefGoogle Scholar
  49. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC (2005) Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26:741–751PubMedCrossRefGoogle Scholar
  50. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMedGoogle Scholar
  51. Wu Y, Denhardt DT, Rittling SR (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156–163PubMedCrossRefGoogle Scholar
  52. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423PubMedCrossRefGoogle Scholar
  53. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH (2001) Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 91:1479–1486PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hui Zhang
    • 1
  • Qing-Hai Ye
    • 1
  • Ning Ren
    • 1
  • Lei Zhao
    • 1
  • Yan-Fang Wang
    • 1
  • Xin Wu
    • 1
  • Hui-Chuan Sun
    • 1
  • Lu Wang
    • 1
  • Bo-Heng Zhang
    • 1
  • Yin-Kun Liu
    • 1
  • Zhao-You Tang
    • 1
  • Lun-Xiu Qin
    • 1
  1. 1.Liver Cancer Institute and Zhongshan HospitalInstitutes of Biomedical Science, Fudan UniversityShanghaiChina

Personalised recommendations